scholarly journals Exploratory studies of extended storage of apheresis platelets in a platelet additive solution (PAS)

Blood ◽  
2014 ◽  
Vol 123 (2) ◽  
pp. 271-280 ◽  
Author(s):  
Sherrill J. Slichter ◽  
Jill Corson ◽  
Mary Kay Jones ◽  
Todd Christoffel ◽  
Esther Pellham ◽  
...  

Key Points Extended apheresis platelet storage is dependent on the collection method, storage in a storage solution, and storage bag composition. The lifespan of the platelet is not intrinsic to the cell, and platelet viability is better maintained in vitro than in vivo.

Transfusion ◽  
2010 ◽  
Vol 50 (11) ◽  
pp. 2376-2385 ◽  
Author(s):  
Ralph R. Vassallo ◽  
John W. Adamson ◽  
Jerome L. Gottschall ◽  
Edward L. Snyder ◽  
Wanda Lee ◽  
...  

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 2108-2108 ◽  
Author(s):  
Sherrill J. Slichter ◽  
Jill Corson ◽  
Mary Kay Jones ◽  
Todd Christoffel ◽  
Esther Pellham ◽  
...  

Abstract Abstract 2108 Poster Board II-85 Background: The FDA has proposed that, at the end of storage, radiolabeled autologous plt recoveries and survivals should be 67% and 58% respectively, of the same donor's “fresh” plt recovery and survival results. Methods: Using 98 normal subjects, 3 different variables were evaluated to determine their effects on post-storage plt recoveries and survivals; i.e., storage solution (plasma and Plasmalyte), apheresis machine [Haemonetics MCS+ (H), Cobe Spectra (CS), or Cobe Trima (CT)], and storage bag (H, CS, or CT). Autologous plts were collected and either infused “fresh” or stored under the conditions of interest. The fresh and stored plts were alternately radiolabeled with either 51Cr or 111In prior to transfusion. Results: Plasma Storage. Both H and CS collected apheresis plts can be stored for 8 days and meet FDA requirements with no differences in post-storage plt recoveries or survivals between the 2 machines (see table). After 9 days of storage, 2 of 5 units (1 H and 1 CS) had pH's of <6.2, and these plts had recoveries of 36% and 26% and survivals of 1.1 and 0.9 days, respectively. Apheresis Machine Storage Time (Days) Storage Bag N PLATELET RECOVERY PLATELET SURVIVAL % % of “Fresh” Days % of “Fresh” Plt Storage In Plasma: H 8 H 10 52 ± 8 79 ± 16 5.3 ± 1.7 78 ± 16 CS 8 CS 10 54 ± 11 75 ± 8 4.7 ± 1.4 62 ± 22 Plt Storage In Plasmalyte: H 7 H 10 52 ± 10 ND 6.0 ± 0.9 ND CS 7 CS 15 47 ± 18* ND 4.3 ± 1.5* ND CT 7 CT 10 40 ± 15** 69 ± 21 5.0 ± 1.6** 64 ± 20 H 9 H 4 55 ± 11 82 ± 20 6.6 ± 1.2 93 ± 39 CS 9 CS 5 27 ± 16** ND 3.6 ± 1.9** ND CT 9 CT 9 32 ± 19*** 58 ± 35 3.7 ± 1.6*** 48 ± 23 CT 9 H 10 44 ± 13 78 ± 16 5.0 ± 0.7 59 ± 7 H 13 H 10 49 ± 10 73 ± 11 4.6 ± 1.0 69 ± 19 CS 13 CS 5 38 ± 10**** ND 2.6 ± 0.9**** ND CS 13 H 5 42 ± 14**** ND 4.6 ± 2.2**** ND Data reported as average ±1 S.D. * Four units had post-storage pH's of <6.0. ** One unit had a post-storage of pH <6.0. *** Two units had post-storage pH's of 6.1. One other unit had a pH of 6.0 and was not injected. **** CS apheresis plts were collected from 5 subjects, and half of the collection was stored in CS bags, and half in H bags. One collection had a pH <6.0 in both bags and was not injected. Plasmalyte Storage. For the H collections, the plts were elutriated using Plasmalyte instead of plasma, and, for the CS and CT collections, the plts were concentrated during collection and re-suspended in Plasmalyte. For all the collections, the final Plasmalyte concentration was 80% with 20% residual plasma. As shown in the table, H collected plts met FDA criteria for 13 days versus 7 days of storage for both CS (FDA criteria not directly tested) and CT collected plts. Even after 7 days of storage, H collected plts were significantly better than CS or CT collected plts with respect to survival (p=0.05), and, after 9 days of storage, H collected plts were significantly better than CS and CT collected plts for both recoveries (p=0.003) and survivals (p<0.001). Recoveries of CS collected plts were better than CT collected plts after 7 days of storage (p=0.01), but the rest of the CS and CT plt recovery and survival data at 7 and 9 days of storage were not different. To determine whether the better results achieved with H plts were because of the machine and/or the storage bag, experiments were performed storing CT or CS collected plts in H bags for 9 or 13 days, respectively. When stored in H bags versus CT bags, 9-day stored CT collected plts had better survivals (p=0.03). Again, CS collected plts stored for 13 days showed a trend for better survivals when stored in H versus CS bags. These data show that both the apheresis machine as well as the storage bag affect the results with the predominant effect being the storage bag. H bag is a ES 3049 PVC compound, and CS and CT bags are PVC with a citrate plasticizer. Low post-storage pH's were found at any storage interval for CS and CT collected plts mainly when stored in their respective bags. pH's <6.2 reduced recoveries by 29% points and survivals by 3.0 days. Therefore, all statistical comparisons between groups were adjusted for the effects of low pH. Conclusion: Apheresis plts can be stored in plasma for 8 days and meet FDA guidelines for plt viability with comparable results between machines and bags. Plt storage in Plasmalyte is effected by both the method of collection as well as the storage bag with the best results achieved with H plts stored in H bags. H plts stored in H bags meet FDA guidelines for 13 days of storage The importance of these results is that extended plt storage can be achieved by using the appropriate combination of storage solution, collection machine, and storage bag. Disclosures: Slichter: Gambro BCT: Research Funding. Off Label Use: Plasmalyte was used as a platelet storage solution.


Transfusion ◽  
2012 ◽  
Vol 53 (5) ◽  
pp. 972-980 ◽  
Author(s):  
Larry J. Dumont ◽  
Jose A. Cancelas ◽  
Sharon Graminske ◽  
Kenneth D. Friedman ◽  
Ralph R. Vassallo ◽  
...  

Transfusion ◽  
2021 ◽  
Vol 61 (S1) ◽  
Author(s):  
Lacey Johnson ◽  
Shuchna Vekariya ◽  
Ben Wood ◽  
Shereen Tan ◽  
Christopher Roan ◽  
...  

2021 ◽  
Vol 17 (10) ◽  
pp. 2071-2084
Author(s):  
Tianjiao Han ◽  
Meiying Wang ◽  
Wenchao Li ◽  
Mingxing An ◽  
Hongzheng Fu

Uric acid is the final product of purine metabolism, and excessive serum uric acid can cause gouty arthritis and uric acid nephropathy. Therefore, lowering the uric acid level and alleviating inflammation in the body are the key points to treating these diseases. A stable nanosuspension of peptide BmK9 was prepared by the precipitation-ultrasonication method. By combining uricase on the surface of a positively charged carrier, a complex consisting of neutral rod-shaped BmK9 and uricase nanoparticles (Nplex) was formed to achieve the delivery of BmK9 and uricase, respectively. The formulation of Nplex has a diameter of 180 nm and drug loading up to 200%, which releases BmK9 and uricase slowly and steadily in drug release tests in vitro. There was significantly improved pharmacokinetic behavior of the two drugs because Nplex prolonged the half-life and increased tissue accumulation. Histological assessments showed that the dual drug Nplex can reduce the inflammation response in acute gouty arthritis and chronic uric acid nephropathy in vivo. In the macrophage system, there was lower toxicity and increased beneficial effect on inflammation with Nplex than free BmK9 or uricase. Collectively, this novel formulation provides a dual drug delivery system that can treat gouty arthritis and uric acid nephropathy.


Vox Sanguinis ◽  
2007 ◽  
Vol 0 (0) ◽  
pp. 071127145052002-??? ◽  
Author(s):  
B. Diedrich ◽  
P. Sandgren ◽  
B. Jansson ◽  
H. Gulliksson ◽  
L. Svensson ◽  
...  

Blood ◽  
2015 ◽  
Vol 125 (18) ◽  
pp. 2806-2814 ◽  
Author(s):  
Stephanie A. Schnell ◽  
Alberto Ambesi-Impiombato ◽  
Marta Sanchez-Martin ◽  
Laura Belver ◽  
Luyao Xu ◽  
...  

Key Points NOTCH1 inhibits apoptosis via HES1-mediated repression of BBC3 in T-ALL. Perhexiline, a HES1 signature modulator drug, has strong antileukemic effects in vitro and in vivo.


Blood ◽  
2016 ◽  
Vol 127 (14) ◽  
pp. 1743-1751 ◽  
Author(s):  
Jesse W. Rowley ◽  
Stéphane Chappaz ◽  
Aurélie Corduan ◽  
Mark M. W. Chong ◽  
Robert Campbell ◽  
...  

Key Points Dicer1 deletion in MKs alters platelet miRNA and mRNA profiles. Dicer1-deficient platelets display increased integrins αIIb and β3 levels and enhanced in vitro and in vivo functional responses.


Blood ◽  
2016 ◽  
Vol 128 (14) ◽  
pp. 1845-1853 ◽  
Author(s):  
Michael Xiang ◽  
Haesook Kim ◽  
Vincent T. Ho ◽  
Sarah R. Walker ◽  
Michal Bar-Natan ◽  
...  

Key PointsThe FDA-approved drug atovaquone is a novel, clinically available inhibitor of STAT3 at standard human plasma concentrations. Atovaquone shows anticancer efficacy in vitro, in vivo, and in a retrospective study of AML patient outcomes after atovaquone treatment.


Sign in / Sign up

Export Citation Format

Share Document